Clene (NASDAQ:CLNN) Share Price Breaks Below 50 Day Moving Average – Here’s What Happened

Clene Inc. (NASDAQ:CLNN – Get Free Report) shares crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $3.89 and traded as low as $3.51. Clene shares last traded at $3.66, with a volume of 123,344 shares traded.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Wall Street Zen raised shares of Clene from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. HC Wainwright reaffirmed a “buy” rating on shares of Clene in a report on Monday, October 19th. Finally, Weiss Ratings raised shares of Clene from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 11th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $34.00.

Get Our Latest Stock Analysis on Clene

Clene Trading Down 6.6%

The stock has a fifty day simple moving average of $3.89 and a two-hundred day simple moving average of $5.10. The firm has a market cap of $52.70 million, a PE ratio of -1.41 and a beta of 1.04.

Clene (NASDAQ:CLNN – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.50. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.07 million. As a group, sell-side analysts predict that Clene Inc. will post -1.05 earnings per share for the current fiscal year.

Institutional Trading of Clene

A hedge fund recently raised its position in Clene stock. State Street Corp raised its position in Clene Inc. (NASDAQ:CLNN – Free Report) by 27.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,901 shares of the company’s stock after purchasing an additional 8,100 shares during the period. State Street Corp owned 0.26% of Clene worth $155,000 at the end of the most recent reporting period. Institutional investors own 23.28% of the company’s stock.

About Clene

(Get Free Report)

Clene Inc. is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. Founded in 2013 and based in Salt Lake City, Utah, the company focuses on research and development rather than marketed medicines. Its lead investigational candidate, CNM-Au8, is a suspension of gold nanocrystals designed to support cellular energy production and protect nerve cells. Clene has studied CNM-Au8 in clinical programs for conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis.

Further Reading

Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.